Moderna (MRNA) Cost of Revenue (2020 - 2026)

Moderna (MRNA) has 7 years of Cost of Revenue data on file, last reported at $955.0 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $955.0 million, up 961.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 18.86% YoY), and the FY2025 annual result was $868.0 million, down 40.71% from the prior year.
• Cost of Revenue rose to $955.0 million in Q1 2026 per MRNA's latest filing, from $452.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $2.2 billion in Q3 2023 and troughed at $90.0 million in Q1 2025.
• A 5-year average of $698.7 million and a median of $731.0 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2024 and 2026: Cost of Revenue tumbled 87.88% in 2024, then soared 961.11% in 2026.
• A 5-year view of Cost of Revenue shows it stood at $400.0 million in 2022, then soared by 132.25% to $929.0 million in 2023, then slipped by 20.45% to $739.0 million in 2024, then sank by 38.84% to $452.0 million in 2025, then soared by 111.28% to $955.0 million in 2026.
• Business Quant data shows MRNA's Cost of Revenue at $955.0 million in Q1 2026, $452.0 million in Q4 2025, and $207.0 million in Q3 2025.